STIC-EIC1600/2900 291575

From: DONNA JAGOE [donna.jagoe@uspto.gov]
Sent: Thursday, April 02, 2009 4:45 PM
To: STIC-EIC1600/2900
Subject: Search Request, Case/Application No.: 10/619426

619426,
, Whole Docu

Requester: DONNA JAGOE (P/1614)
Art Unit: GROUP ART UNIT 1614
Employee Number:
Office Location: REM 3A70
Phone Number: (571)272-0576

Case/Application number: 10/619426
Priority Filing Date: 11/15/1996
Format for Search Results: Score
Meaning of unusual acronyms or initialisms:
HIV-human immunodeficiency virus

Identify the novelty:
method of treating HIV

Additional comments:
Please search the compounds of claims 21-25 for the method of treating HIV

Attachment: Yes (619426, Claims, Whole Document.pdf)

INVENTOR SEARCH

=> fil hcapl; d que nos 129; fil uspatf; d que nos 140
FILE 'HCAPLUS' ENTERED AT 09:49:13 ON 07 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 6 Apr 2009 (20090406/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

L10		STR
L12	228	SEA FILE=REGISTRY SSS FUL L10
L19	1	SEA FILE=HCAPLUS SPE=ON ABB=ON US2003-619426/AP
L20	243	SEA FILE=HCAPLUS SPE=ON ABB=ON TRACEY K?/AU
L21	1949	SEA FILE=HCAPLUS SPE=ON ABB=ON COHEN P?/AU
L22	99	SEA FILE=HCAPLUS SPE=ON ABB=ON BUKRINSKY M?/AU
L23	23	SEA FILE=HCAPLUS SPE=ON ABB=ON SCHMIDTMAYEROVA H?/AU
L24	164	SEA FILE=HCAPLUS SPE=ON ABB=ON L12
L25	64502	SEA FILE=HCAPLUS SPE=ON ABB=ON HUMAN IMMUNODEFICIENCY VIRUS+PFT,NT/CT
L26	25011	SEA FILE=HCAPLUS SPE=ON ABB=ON "AIDS (DISEASE)"+PFT/CT
L27	24255	SEA FILE=HCAPLUS SPE=ON ABB=ON ANTI-AIDS AGENTS/CT
L29	3	SEA FILE=HCAPLUS SPE=ON ABB=ON (L19 OR L20 OR L21 OR L22 OR L23) AND L24 AND (L25 OR L26 OR L27)

FILE 'USPATFULL' ENTERED AT 09:49:14 ON 07 APR 2009

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 7 Apr 2009 (20090407/PD)
FILE LAST UPDATED: 7 Apr 2009 (20090407/ED)
HIGHEST GRANTED PATENT NUMBER: US7516497
HIGHEST APPLICATION PUBLICATION NUMBER: US20090089907
CA INDEXING IS CURRENT THROUGH 7 Apr 2009 (20090407/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 7 Apr 2009 (20090407/PD)

```
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2008

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.


L10             STR
L12         228 SEA FILE=REGISTRY SSS FUL L10
L31          63 SEA FILE=USPATFULL SPE=ON  ABB=ON  L12
L32          66 SEA FILE=USPATFULL SPE=ON  ABB=ON  TRACEY K?/AU
L33         147 SEA FILE=USPATFULL SPE=ON  ABB=ON  COHEN P?/AU
L34          17 SEA FILE=USPATFULL SPE=ON  ABB=ON  BUKRINSKY M?/AU
L35           3 SEA FILE=USPATFULL SPE=ON  ABB=ON  SCHMIDTMAYEROVA H?/AU
L37       63858 SEA FILE=USPATFULL SPE=ON  ABB=ON  HIV# OR HUMAN(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L38      219327 SEA FILE=USPATFULL SPE=ON  ABB=ON  AIDS OR ACQUIRED(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L39       56681 SEA FILE=USPATFULL SPE=ON  ABB=ON  RETROVIR? OR ANTIRETROVIR?
L40           4 SEA FILE=USPATFULL SPE=ON  ABB=ON  L31 AND (L32 OR L33 OR L34
                OR L35) AND (L37 OR L38 OR L39)


=> dup rem l29,l40
FILE 'HCAPLUS' ENTERED AT 09:49:18 ON 07 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:49:18 ON 07 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L40
L57             7 DUP REM L29 L40 (0 DUPLICATES REMOVED)
                ANSWERS '1-3' FROM FILE HCAPLUS
                ANSWERS '4-7' FROM FILE USPATFULL

=> d ibib abs hitind hitstr 1-7

L57  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:696765  HCAPLUS  Full-text
DOCUMENT NUMBER:          139:207785
TITLE:                    Inhibition of inflammatory cytokine production by
                          stimulation of brain muscarinic receptors
INVENTOR(S):              Ivanova, Svetlana M.; Tracey, Kevin J.
PATENT ASSIGNEE(S):       North Shore-Long Island Jewish Research Institute, USA
SOURCE:                   PCT Int. Appl., 56 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    -------------------    --------
     WO 2003072135        A2    20030904    WO 2003-US5873         20030226
     WO 2003072135        A3    20040722
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2476896	A1	20030904	CA 2003-2476896		20030226
AU 2003217747	A1	20030909	AU 2003-217747		20030226
US 20040048795	A1	20040311	US 2003-375696		20030226
EP 1487494	A2	20041222	EP 2003-713709		20030226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005522457	T	20050728	JP 2003-570879		20030226
AU 2007202036	A1	20070524	AU 2007-202036		20070507
PRIORITY APPLN. INFO.:			US 2002-360082P	P	20020226
			AU 2003-217747	A3	20030226
			WO 2003-US5873	W	20030226

AB Methods are provided for inhibiting proinflammatory cytokine release or inflammation in a vertebrate. The methods comprise activating a brain muscarinic receptor of the vertebrate, or directly stimulating a vagus nerve pathway in the brain of the vertebrate. Also provided are methods for conditioning a vertebrate to inhibit the release of a proinflammatory cytokine or reduce inflammation in the vertebrate upon experiencing a sensory stimulus. The methods comprise (a) activating a muscarinic brain receptor or directly stimulating the vagus nerve pathway in the brain of the vertebrate and providing the sensory stimulus to the vertebrate within a time period sufficient to create an association between the stimulus and the activation of the brain muscarinic receptor; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the inflammation to be reduced by the sensory stimulus alone.

IC ICM A61K045-00
ICS A61K031-341; A61K038-16; A61K031-27; A61P029-00
CC 1-7 (Pharmacology)

IT Allergy
Allergy inhibitors
Anaphylaxis
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antiulcer agents
Arthritis
Asthma
Atherosclerosis
Behcet's syndrome
Burn
Cachexia
Cardiovascular agents
Celiac disease
Cystic fibrosis
Dermatitis
Dermatomyositis
Emphysema
Encephalitis
Fever and Hyperthermia
Gastrointestinal agents
Gout
Hay fever
Hepatitis

Hepatitis B virus
Hepatitis C virus
Hodgkin's disease
Human
Human herpesvirus
Human immunodeficiency virus
Immunosuppressants
Inflammation
Influenza virus
Ischemia
Lupus erythematosus
Malaria
Meningitis
Multiple sclerosis
Muscarinic agonists
Myasthenia gravis
Necrosis
Nervous system agents
Osteomyelitis
Paralysis
Periodontium, disease
Psoriasis
Respiratory distress syndrome
Respiratory syncytial virus
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Sepsis
Septicemia
Shock (circulatory collapse)
Sunburn
Urticaria
Wart
(inflammatory cytokine production inhibition by stimulation of brain muscarinic receptors)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); BIOL (Biological study)
(inflammatory cytokine production inhibition by stimulation of brain muscarinic receptors)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); BIOL (Biological study)
(inflammatory cytokine production inhibition by stimulation of brain muscarinic receptors)

RN 164301-51-3 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



4 HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:221229 HCAPLUS Full-text
DOCUMENT NUMBER: 133:29514
TITLE: Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120
AUTHOR(S): Milligan, E. D.; Mehmert, K. K.; Hinde, J. L.; Harvey, L. O.; Martin, D.; Tracey, K. J.; Maier, S. F.; Watkins, L. R.
CORPORATE SOURCE: Department of Psychology, University of Colorado at Boulder, Boulder, CO, USA
SOURCE: Brain Research (2000), 861(1), 105-116
CODEN: BRREAP; ISSN: 0006-8993
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Astrocytes and microglia in the spinal cord have recently been reported to contribute to the development of peripheral inflammation-induced exaggerated pain states. Both lowering of thermal pain threshold (thermal hyperalgesia) and lowering of response threshold to light tactile stimuli (mech. allodynia) have been reported. The notion that spinal cord glia are potential mediators of such effects is based on the disruption of these exaggerated pain states by drugs thought to preferentially affect glial function. Activation of astrocytes and microglia can release many of the same substances that are known to mediate thermal hyperalgesia and mech. allodynia. The aim of the present series of studies was to determine whether exaggerated pain states could also be created in rats by direct, intraspinal immune activation of astrocytes and microglia. The immune stimulus used was peri-spinal (intrathecal, i.t.) application of the Human Immunodeficiency Virus type 1 (HIV-1) envelope glycoprotein, gp120. This portion of HIV-1 is known to bind to and activate microglia and astrocytes. Robust thermal hyperalgesia (tail-flick, TF, and Hargreaves tests) and mech. allodynia (von Frey and touch-evoked agitation tests) were observed in response to i.t. gp120. Heat denaturing of the complex protein structure of gp120 blocked gp120-induced thermal hyperalgesia. Lastly, both thermal hyperalgesia and mech. allodynia to i.t. gp120 were blocked by spinal pretreatment with drugs (fluorocitrate and CNI-1493) thought to preferentially disrupt glial function.

CC 15-8 (Immunochemistry)
Section cross-reference(s): 1

IT Human immunodeficiency virus 1
(thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120)
IT 357-89-1 164301-51-3, Cni-1493
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120 blocking by)
IT 164301-51-3, Cni-1493
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120 blocking by)
RN 164301-51-3 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:338118 HCAPLUS Full-text
DOCUMENT NUMBER: 129:36435
ORIGINAL REFERENCE NO.: 129:7529a,7532a
TITLE: Guanylhydrazones useful for treating diseases associated with T-cell activation
INVENTOR(S): Tracey, Kevin; Cohen, Pamela; Bukrinsky, Michael; Schmidtmayerova, Helena
PATENT ASSIGNEE(S): Picower Institute for Medical Research, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 9820868          A1    19980522    WO 1997-US20670        19971114
         W:  AL, AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KR,
             KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SI, SK, TR, UA, UZ, AM,
             AZ, KG, MD, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE
     CA 2271693          A1    19980522    CA 1997-2271693        19971114
     CA 2271693          C     20090120
     AU 9854360          A     19980603    AU 1998-54360          19971114
     AU 746647           B2    20020502
     EP 963197           A1    19991215    EP 1997-948263         19971114
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     US 6143728          A     20001107    US 1997-970973         19971114
     JP 2001503775       T     20010321    JP 1998-522801         19971114
     US 6673777          B1    20040106    US 2000-705581         20001102
     AU 2002300386       A1    20030206    AU 2002-300386         20020802
     AU 2002300386       B2    20050728
     US 20040171695      A1    20040902    US 2003-619426         20030716 <--
PRIORITY APPLN. INFO.:                      US 1996-31061P      P  19961115
                                            AU 1998-54360       A3 19971114
                                            US 1997-970973      A3 19971114
                                            WO 1997-US20670     W  19971114
                                            US 2000-705581      A1 20001102
OTHER SOURCE(S):         MARPAT 129:36435
AB   There is disclosed a method for treating diseases and disorders involving T-
     cell activation and HIV-infection, using the p38 mitogen-activated protein
     kinase (MAPK) signaling pathway as a target for intervention. There is further
     disclosed a use for guanylhydrazone-substituted compds. to treat diseases and
     disorders related to T cell activation and HIV-infection.
IC   ICM  A61K031-15
     ICS  A61K031-155; C07C233-05; C07C281-18
CC   1-5 (Pharmacology)
IT   AIDS (disease)
     Antidiabetic agents
     Antirheumatic agents
     Antiviral agents
     Autoimmune disease
       Human immunodeficiency virus
       Human immunodeficiency virus 1
     Multiple sclerosis
     Psoriasis
     Rheumatoid arthritis
     Transplant rejection
        (guanylhydrazones useful for treating diseases associated with T-cell
        activation)
IT   164301-51-3, CNI-1493
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (guanylhydrazones useful for treating diseases associated with T-cell
        activation)
IT   164301-51-3, CNI-1493
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (guanylhydrazones useful for treating diseases associated with T-cell
        activation)
RN   164301-51-3  HCAPLUS
CN   Decanediamide, N1,N10-bis[3,5-bis[1-[2-
```

(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2004:221923 USPATFULL Full-text
TITLE:	Guanylhydrazones useful for treating diseases associated with T cell activation
INVENTOR(S):	Tracey, Kevin J., Old Greenwich, CT, UNITED STATES Cohen, Pamela, Tenafly, NJ, UNITED STATES Bukrinsky, Michael, Glen Head, NY, UNITED STATES Schmidtmayerova, Helena, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040171695	A1	20040902
APPLICATION INFO.:	US 2003-619426	A1	20030716 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-705581, filed on 2 Nov 2000, GRANTED, Pat. No. US 6673777 Division of Ser. No. US 1997-970973, filed on 14 Nov 1997, GRANTED, Pat. No. US 6143728		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31061P	19961115 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Supervisor, Patent Prosecution Services, PIPER RUDNICK LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	1115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein

kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 164301-51-3, CNI-1493
(guanylhydrazones useful for treating diseases associated with T-cell activation)
RN 164301-51-3 USPATFULL
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

STRUCTURE SEARCH

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 09:49:52 ON 07 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 APR 2009  HIGHEST RN 1132745-38-0
DICTIONARY FILE UPDATES:   6 APR 2009  HIGHEST RN 1132745-38-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d stat que l12; fil hcapl; d que nos 156
L10             STR
```




```
VAR G1=10/14/16/18/24/29/35/39
VAR G2=43/54/57/59/46
VAR G3=H/ME
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS  AT   2 13 14 15 16 17 20 26 32 36 40 58 60 61 62 63
GGCAT    IS MCY  LOC  UNS  AT   2
GGCAT    IS MCY  LOC  UNS  AT  13
GGCAT    IS MCY  LOC  UNS  AT  14
```

```
GGCAT   IS MCY  LOC  UNS  AT  15
GGCAT   IS MCY  LOQ  UNS  AT  16
GGCAT   IS MCY  LOC  UNS  AT  17
GGCAT   IS MCY  LOC  UNS  AT  58
GGCAT   IS MCY  LOC  UNS  AT  60
GGCAT   IS MCY  LOC  UNS  AT  61
GGCAT   IS MCY  LOC  UNS  AT  62
GGCAT   IS MCY  LOC  UNS  AT  63
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E5 C  E1 N  AT  16

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  57

STEREO ATTRIBUTES: NONE
L12         228 SEA FILE=REGISTRY SSS FUL L10

100.0% PROCESSED   22029 ITERATIONS                          228 ANSWERS
SEARCH TIME: 00.00.01



FILE 'HCAPLUS' ENTERED AT 09:50:03 ON 07 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 6 Apr 2009  (20090406/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


L10             STR
L12         228 SEA FILE=REGISTRY SSS FUL L10
L24         164 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L12
L25       64502 SEA FILE=HCAPLUS SPE=ON  ABB=ON  HUMAN IMMUNODEFICIENCY
                VIRUS+PFT,NT/CT
```

```
L26       25011 SEA FILE=HCAPLUS SPE=ON  ABB=ON  "AIDS (DISEASE)"+PFT/CT
L27       24255 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTI-AIDS AGENTS/CT
L30          13 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L24 AND (L25 OR L26 OR L27)
L49       24429 SEA FILE=HCAPLUS SPE=ON  ABB=ON  RETROVIR?/OBI OR ANTIRETROVIR?
                /OBI
L50           3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L24 AND L49
L51          14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L50 OR L30)
L52          11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L51 AND PATENT/DT
L53           3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L51 NOT L52
L54           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L53 AND PY<1997
L55           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L51 AND (PD<19961114 OR
                AD<19961114 OR PRD<19961114)
L56           0 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L54 OR L55)


=> d que nos l51; s l51 not l29
L10               STR
L12           228 SEA FILE=REGISTRY SSS FUL L10
L24           164 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L12
L25         64502 SEA FILE=HCAPLUS SPE=ON  ABB=ON  HUMAN IMMUNODEFICIENCY
                VIRUS+PFT,NT/CT
L26         25011 SEA FILE=HCAPLUS SPE=ON  ABB=ON  "AIDS (DISEASE)"+PFT/CT
L27         24255 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTI-AIDS AGENTS/CT
L30            13 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L24 AND (L25 OR L26 OR L27)
L49         24429 SEA FILE=HCAPLUS SPE=ON  ABB=ON  RETROVIR?/OBI OR ANTIRETROVIR?
                /OBI
L50             3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L24 AND L49
L51            14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L50 OR L30)


L58            11 L51 NOT L29    L29=INVENTOR SEARCH ANSWER SET

=> fil uspatf; d que nos l42; d que nos l41; s l41 not l40
FILE 'USPATFULL' ENTERED AT 09:50:30 ON 07 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 7 Apr 2009 (20090407/PD)
FILE LAST UPDATED: 7 Apr 2009 (20090407/ED)
HIGHEST GRANTED PATENT NUMBER: US7516497
HIGHEST APPLICATION PUBLICATION NUMBER: US20090089907
CA INDEXING IS CURRENT THROUGH 7 Apr 2009 (20090407/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 7 Apr 2009 (20090407/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2008

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.


L10               STR
L12           228 SEA FILE=REGISTRY SSS FUL L10
L31            63 SEA FILE=USPATFULL SPE=ON  ABB=ON  L12
L37         63858 SEA FILE=USPATFULL SPE=ON  ABB=ON  HIV# OR HUMAN(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L38        219327 SEA FILE=USPATFULL SPE=ON  ABB=ON  AIDS OR ACQUIRED(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L39         56681 SEA FILE=USPATFULL SPE=ON  ABB=ON  RETROVIR? OR ANTIRETROVIR?
L41            25 SEA FILE=USPATFULL SPE=ON  ABB=ON  L31 AND (L37 OR L38 OR L39)
```

```
L42           0 SEA FILE=USPATFULL SPE=ON  ABB=ON  L41 AND (PD<19961114 OR
                AD<19961114 OR PRD<19961114)



L10             STR
L12         228 SEA FILE=REGISTRY SSS FUL L10
L31          63 SEA FILE=USPATFULL SPE=ON  ABB=ON  L12
L37       63858 SEA FILE=USPATFULL SPE=ON  ABB=ON  HIV# OR HUMAN(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L38      219327 SEA FILE=USPATFULL SPE=ON  ABB=ON  AIDS OR ACQUIRED(W)(IMMUN?
                DEFICIEN? OR IMMUNODEFIC?)
L39       56681 SEA FILE=USPATFULL SPE=ON  ABB=ON  RETROVIR? OR ANTIRETROVIR?
L41          25 SEA FILE=USPATFULL SPE=ON  ABB=ON  L31 AND (L37 OR L38 OR L39)



L59          21 L41 NOT L40    L40=INVENTOR SEARCH ANSWER SET

=> dup rem l58,l59
FILE 'HCAPLUS' ENTERED AT 09:50:36 ON 07 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:50:36 ON 07 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L58
PROCESSING COMPLETED FOR L59
L60           29 DUP REM L58 L59 (3 DUPLICATES REMOVED)
                ANSWERS '1-11' FROM FILE HCAPLUS
                ANSWERS '12-29' FROM FILE USPATFULL

=> d ibib abs hitind hitstr 1-29; fil hom

L60  ANSWER 1 OF 29  HCAPLUS  COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2006:982167  HCAPLUS  Full-text
DOCUMENT NUMBER:          145:348597
TITLE:                    Use of phenylmethimazoles, methimazole derivatives,
                          and tautomeric cyclic thiones for the treatment of
                          autoimmune/inflammatory diseases associated with
                          toll-like receptor overexpression
INVENTOR(S):              Kohn, Leonard D.; Harii, Norikazu; Benavides-Peralta,
                          Uruguaysito; Gonzalez-Murguiondo, Mariana; Lewis,
                          Christopher J.; Napolitano, Giorgio; Giuliani,
                          Cesidio; Malgor, Ramiro; Goetz, Douglas J.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 102 pp., Cont.-in-part of U.S.
                          Ser. No. 912,948.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     US 20060211752       A1    20060921    US 2005-130922         20050517
     US 20050209295       A1    20050922    US 2004-801986         20040316
```

```
     AU 2004317993          A1    20051013    AU 2004-317993          20040316
     CA 2559712             A1    20051013    CA 2004-2559712         20040316
     EP 1725230             A1    20061129    EP 2004-821836          20040316
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     JP 2007529510          T     20071025    JP 2007-503869          20040316
     US 20060058365         A1    20060316    US 2004-912948          20040806
     AU 2006247504          A1    20061123    AU 2006-247504          20060511
     CA 2606769             A1    20061123    CA 2006-2606769         20060511
     WO 2006124676          A1    20061123    WO 2006-US18554         20060511
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
            KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
            MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
            SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
            VN, YU, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
     EP 1896015             A1    20080312    EP 2006-770302          20060511
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
     JP 2008545651          T     20081218    JP 2008-512377          20060511
PRIORITY APPLN. INFO.:                        US 2004-801986      A2  20040316
                                              US 2004-912948      A2  20040806
                                              WO 2004-US7888      A   20040316
                                              US 2005-130922      A   20050517
                                              WO 2006-US18554     W   20060511
OTHER SOURCE(S):          MARPAT 145:348597
```

AB The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

```
INCL 514389000
CC   1-7 (Pharmacology)
     Section cross-reference(s): 9
IT   Human immunodeficiency virus
        (infection; use of phenylmethimazoles, methimazole derivs., and
        tautomeric cyclic thiones for treatment of autoimmune/inflammatory
        diseases associated with toll-like receptor overexpression)
IT   AIDS (disease)
     Acute-phase response
```

Addison's disease
Alopecia
Animal cell
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Antifibrotic agents
Antihypertensives
Antimalarials
Antiphospholipid syndrome
Antirheumatic agents
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Autoimmune disease
Behcet's syndrome
Blood vessel, disease
Cachexia
Calcium channel blockers
Cardiovascular agents
Cardiovascular system, disease
Chronic lymphocytic leukemia
Combination chemotherapy
Dendritic cell
Dermatitis
Dermatomyositis
Diabetes mellitus
Diagnosis
Drug delivery systems
Drug screening
Dyslipidemia
Dyspnea
Emphysema
Endotoxemia
Fibrosis
Food allergy
Granulomatous disease
Graves' disease
Hodgkin's disease
Human
Hypercholesterolemia
Hyperglycemia
Hyperlipidemia
Hypertension
Hypertriglyceridemia
Hypolipemic agents
Hypothyroidism
Inflammation
Ischemia
Macrophage
Malaria
Melanoma
Metabolic disorders
Monocyte

Multiple myeloma
Multiple sclerosis
Myasthenia gravis
Myeloid leukemia
Neoplasm
Osteoarthritis
Platelet aggregation
Platelet aggregation inhibitors
Prognosis
Prophylaxis
Pruritus
Psoriasis
Rheumatic fever
Rheumatoid arthritis
Septicemia
Signal transduction, biological
Sjogren syndrome
Thrombosis
Tooth
Transplant rejection
Vitiligo
(use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression)

IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 51-64-9, Dexamphetamine 53-03-2, Prednisone 53-86-1, Indomethacin 56-03-1D, Biguanide, derivs. 58-56-0, Vitamin B6 hydrochloride 59-30-3, Folic acid, biological studies 59-30-3D, Folic acid, esters and salts 59-67-6, Niacin, biological studies 68-19-9, Vitamin B12 122-09-8, Phentermine 300-62-9D, Amphetamine, derivs. 378-44-9, Betamethasone 458-24-2, Fenfluramine 461-78-9, Chlorphentermine 1406-18-4, Vitamin E 2030-63-9, Clofazimine 2295-31-0D, Thiazolidinedione, derivs. 3239-44-9, Dexfenfluramine 6484-89-5, Sodium folate 7235-40-7, β-Carotene 8059-24-3, Vitamin B6 8059-24-3D, Vitamin B6, salts 9004-10-8D, Insulin, analogs 10389-73-8, Clortermine 14261-75-7, Cloforex 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 23288-49-5, Probucol 24280-93-1, Mycophenolic acid 25614-03-3, Bromocriptine 36322-90-4, Piroxicam 42399-41-7, Diltiazem 51147-03-6 51333-22-3, Budesonide 53123-88-9, Rapamycin 54739-18-3, Fluvoxamine 54870-28-9D, Meglitinide, derivs. 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 62510-56-9, Picilorex 62571-86-2, Captopril 75330-75-5, Lovastatin 75706-12-6, Leflunomide 75847-73-3, Enalapril 79617-96-2, Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin 89750-14-1, Glucagon-like peptide-1 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 106650-56-0, Sibutramine 114798-26-4, Losartan 120210-48-2, Tenidap 121009-77-6 129024-87-9, Doprexin 129318-43-0, Alendronate sodium 134523-00-5, Atorvastatin 137109-78-5, OR1384 145599-86-6, Cerivastatin 147191-91-1, Priliximab 147511-69-1, Pitavastatin 159183-92-3, L750355 162011-90-7, Rofecoxib 164301-51-3, CNI-1493 168273-06-1, SR-141716 169494-85-3, Leptin 169590-42-5, Celecoxib 170277-31-3, Infliximab 185243-69-0, Etanercept 244081-42-3, AJ9677 282526-98-1, ATL 962 335149-25-2, CP 331648 444069-80-1, Axokine 464213-10-3, SLV-319 782482-05-7, BVT 933
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for treatment of autoimmune/inflammatory

diseases associated with toll-like receptor overexpression)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; use of phenylmethimazoles, methimazole derivs., and tautomeric cyclic thiones for treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

L60 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:904349 HCAPLUS Full-text
DOCUMENT NUMBER: 143:248278
TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor
INVENTOR(S): Hamann, Lawrence G.; Bi, Yingzhi; Manfredi, Mark C.; Nirschl, Alexandra A.; Sutton, James C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050187267	A1	20050825	US 2005-48439	20050201
PRIORITY APPLN. INFO.:			US 2004-541869P P	20040204

OTHER SOURCE(S): CASREACT 143:248278; MARPAT 143:248278
GI



I II



III

AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. Pharmaceutical compns. comprising I are disclosed.

IC ICM A61K031-433
ICS A61K031-4015; C07D498-04

INCL 514362000; 514423000; 548537000; 548126000

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

IT AIDS (disease)
Acne
Adenoma
Aging, animal
Alopecia
Alzheimer's disease
Anemia (disease)
Anorexia
Anti-AIDS agents
Anti-Alzheimer's agents
Antiarthritics
Antidepressants
Antiobesity agents
Antitumor agents
Bladder, neoplasm
Brain, neoplasm
Burn
Cachexia
Cardiovascular agents
Chemotherapy

Cognition
Coma
Combination chemotherapy
Contraceptives
Cushing's syndrome
Dialysis
Eating disorders
Feeding
Heart, disease
Hirsutism
Homeostasis
Human
Hypothermia
Kidney, neoplasm
Lipodystrophy
Liver, neoplasm
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Multiple sclerosis
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Potassium channel openers
Preeclampsia
Prostate gland, neoplasm
Reperfusion
Seborrhea
Sexual disorders
Skin, neoplasm
Sleep
Sleep disorders
Spermatogenesis
Stress, biological
Transplant and Transplantation
Wound healing
(preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 50-02-2 50-07-7 50-18-0 50-44-2 50-76-0, Actinomycin D 50-78-2
50-81-7, L-Ascorbic acid, biological studies 51-21-8 51-64-9 52-01-7
52-24-4 52-53-9 53-03-2 53-19-0 53-43-0 53-86-1 54-31-9
55-86-7 55-98-1 56-03-1, Imidodicarbonimidic diamide 56-53-1
57-22-7 57-47-6 57-83-0, Pregn-4-ene-3,20-dione, biological studies
58-22-0 58-32-2 58-54-8 58-55-9, biological studies 58-93-5
58-94-6 59-05-2 59-30-3, biological studies 60-27-5 61-90-5,
L-Leucine, biological studies 68-19-9, Vitamin B12 68-26-8, Retinol
71-58-9 73-48-3 76-60-8 77-36-1 91-33-8 122-09-8 127-07-1
133-67-5 135-07-9 135-09-1 147-94-4 148-56-1 148-82-3
151-56-4, Aziridine, biological studies 154-42-7 154-93-8 155-97-5
302-79-4, Retinoic acid 303-98-0 305-03-3 321-64-2 346-18-9
378-44-9 396-01-0 439-14-5 541-15-1 595-33-5 604-75-1 625-08-1
630-60-4 645-05-6 657-24-9 671-16-9 797-63-7 846-49-1
865-21-4, Vincaleukoblastine 1200-22-2 1406-16-2, Vitamin D
1406-18-4, Vitamin E 1605-68-1 2030-63-9 2295-31-0,
2,4-Thiazolidinedione 2609-46-3 2998-57-4 3056-17-5 3778-73-2
4205-90-7 4291-63-8 4342-03-4 4375-07-9 5630-53-5 7439-95-4,
Magnesium, biological studies 7440-09-7, Potassium, biological studies
7440-47-3, Chromium, biological studies 7440-66-6, Zinc, biological
studies 7440-70-2, Calcium, biological studies 7481-89-2 7782-49-2,

Selenium, biological studies 8059-24-3, Vitamin B6 9002-64-6, Parathormone 9002-71-5, Thyrotropin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9015-68-3, Asparaginase 9041-93-4 10238-21-8 10246-75-0 10540-29-1 11056-06-7, Bleomycin 13010-20-3 13010-47-4 13311-84-7 13909-09-6 14769-73-4 14838-15-4 15056-34-5, 1-Triazene 15663-27-1 15687-27-1 16984-48-8, Fluoride, biological studies 18378-89-7 18883-66-4 20830-81-3 21679-14-1 21829-25-4 22204-53-1 22232-71-9 24305-27-9 25316-40-9 26027-38-3 26538-44-3 28395-03-1 29094-61-9 29767-20-2 30516-87-1 33069-62-4 33419-42-0 35212-22-7 36085-73-1 36322-90-4 36505-84-7 38304-91-5 40180-04-9 41575-94-4 42399-41-7 51333-22-3 52205-73-9 53714-56-0 53910-25-1 54870-28-9 54910-89-3 55142-85-3 55294-15-0 56180-94-0 57982-77-1 58095-31-1 58957-92-9 59729-33-8 59865-13-3, Cyclosporin A 61869-08-7 62571-86-2 66376-36-1 67763-96-6, Insulin-like growth factor I 67763-97-7, Insulin-like growth factor II 69655-05-6 73963-72-1 75330-75-5 75425-66-0 75847-73-3 76547-98-3 79517-01-4 79617-96-2 79902-63-9 81093-37-0 81872-10-8 82924-03-6 83366-66-9 83435-66-9 84449-90-1 85441-61-8 87333-19-5 87616-84-0 88150-42-9 88768-40-5 93479-97-1 96829-58-2 97240-79-4 97322-87-7 98048-97-6 98319-26-7 100286-90-6 104987-11-3 105462-24-6 106650-56-0 107724-20-9 110942-02-4 111025-46-8 111223-26-8 113665-84-2 114798-26-4 114977-28-5 116644-53-2 116680-01-4 117091-64-2 120014-06-4 121181-53-1 122111-03-9 122320-73-4 123441-03-2 123774-72-1 123948-87-8 125317-39-7 127779-20-8 129318-43-0 134523-00-5 134678-17-4 135062-02-1 137109-78-5 137862-53-4 138402-11-6 139755-83-2 141626-36-0 141750-63-2 143443-90-7 143653-53-6 144494-65-5 147030-48-6 147191-91-1 147511-69-1 149845-06-7 150322-43-3 155213-67-5 157810-81-6 158861-67-7 159183-92-3 159752-10-0 160135-92-2 162011-90-7 164301-51-3 167305-00-2 169590-42-5 170277-31-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 164301-51-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

L60 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:824492 HCAPLUS Full-text
DOCUMENT NUMBER: 143:222525
TITLE: Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function, preparation thereof, and use with other agents
INVENTOR(S): Nirschl, Alexandra A.; Hamann, Lawrence G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050182105	A1	20050818	US 2005-48437		20050201
PRIORITY APPLN. INFO.:			US 2004-541780P	P	20040204
OTHER SOURCE(S):	MARPAT 143:222525				

GI



I

AB A method is provided for treating androgen receptor-associated conditions, such as age-related diseases, e.g. sarcopenia, employing a compound I [R1 = CN, H; X = O, S; R2 = (substituted) alkyl, (substituted) cycloalkyl, etc; R3, R4 = H, (substituted) alkyl, etc.; G = (substituted) aryl, (substituted) heteroaryl], or a pharmaceutically acceptable salt or prodrug ester thereof. Preparation of selected I is described. I may be used in combination with other agents.

IC ICM A61K031-4439
ICS A61K031-44
INCL 514340000; 514344000
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 27
IT 5-HT reuptake inhibitors
AIDS (disease)
Acne
Alkylating agents, biological
Alopecia
Alzheimer's disease
Anabolic agents
Androgen replacement therapy
Anemia (disease)
Angiotensin receptor antagonists
Anorexia
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents

Antiandrogens
Antiarthritics
Antibiotics
Anticholesteremic agents
Anticoagulants
Antidepressants
Antidiabetic agents
Antiestrogens
Antihypertensives
Antiobesity agents
Antitumor agents
Antiviral agents
Anxiety
Anxiolytics
Appetite depressants
Bladder, neoplasm
Bone resorption inhibitors
Brain, neoplasm
Burn
Calcium channel blockers
Cardiovascular agents
Chemotherapy
Cognition enhancers
Cognitive disorders
Coma
Combination chemotherapy
Contraceptives
Cushing's syndrome
Cytotoxic agents
Diabetes mellitus
Dietary supplements
Diuretics
Drug delivery systems
Eating disorders
GABA antagonists
Gastrointestinal agents
Hirsutism
Hormone replacement therapy
Human
  Human immunodeficiency virus
Hypercholesterolemia
Hyperlipidemia
Hypertension
Hypolipemic agents
Hypothermia
Immunomodulators
Immunosuppression
Inflammation
Kidney, neoplasm
Lipodystrophy
Liver, neoplasm
Lung, neoplasm
Lymphatic system, neoplasm
Mammary gland, neoplasm
Musculoskeletal diseases
Mycobacterium BCG
Natural products, pharmaceutical
Nervous system agents
Obesity
Osteoarthritis

Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Periodontium, disease
Platelet aggregation inhibitors
Potassium channel openers
Preeclampsia
Pregnancy
Prophylaxis
Prostate gland, neoplasm
Radiotherapy
Seborrhea
Selective estrogen receptor modulators
Sexual disorders
Skin, neoplasm
Sleep disorders
Spermatogenesis
Stress, animal
Thrombolytics
Thrombosis
Thromboxane receptor antagonists
Wound
Wound healing promoters
α-Adrenoceptor agonists
β-Adrenoceptor antagonists
β3-Adrenoceptor agonists
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

IT 147030-48-6, KB-130015 147191-91-1, Priliximab 147511-69-1, Pitavastatin 147526-32-7, NK-104 149845-06-7, Saquinavir mesylate 150322-43-3, CS-747 155213-67-5, Ritonavir 157810-81-6, Indinavir sulfate 158861-67-7, GHRP-2 159183-92-3, L750355 159752-10-0, MK-677 160135-92-2, Gemopatrilat 162011-90-7, Vioxx 164301-51-3, CNI-1493 165456-81-5 167305-00-2, Omapatrilat 169590-42-5, Celebrex 170277-31-3, Infliximab 171596-29-5, IC-351 173937-91-2, Atrasentan 174722-31-7, Rituximab 184036-34-8, Sitaxsentan 185243-69-0, Enbrel 186692-73-9, Epothilone C 186692-73-9D, Epothilone C, analogs 188627-80-7, Eptifibatide 189453-10-9, Epothilone D 189453-10-9D, Epothilone D, analogs 193079-69-5, NN703 193273-66-4, CP424391 201049-37-8, Epothilone E 201049-37-8D, Epothilone E, analogs 208518-52-9, Epothilone F 208518-52-9D, Epothilone F, analogs 220541-10-6, LY444711 244081-42-3, AJ9677 282526-98-1, ATL-962 287714-41-4 335149-25-2, CP 331648 420097-93-4 444069-80-1, Axokine 681125-90-6, Epithilone A 681125-90-6D, Epithilone A, analogs 681125-91-7, Epithilone B 681125-91-7D, Epithilone B, analogs 862366-09-4 862366-16-3 862366-20-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

L60 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:352859 HCAPLUS Full-text
DOCUMENT NUMBER: 148:394354
TITLE: Compositions and methods for treatment of viral diseases
INVENTOR(S): Johansen, Lisa M.; Owens, Christopher M.; Mawhinney, Christina; Chappell, Todd W.; Brown, Alexander T.; Frank, Michael G.; Altmeyer, Ralf
PATENT ASSIGNEE(S): Combinatorx (Singapore) Pre. Ltd., Singapore
SOURCE: PCT Int. Appl., 237pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008033466	A2	20080320	WO 2007-US19932	20070913
WO 2008033466	A3	20081211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20080161324	A1	20080703	US 2007-900893	20070913
PRIORITY APPLN. INFO.:			US 2006-844463P	P 20060914
			US 2006-874061P	P 20061211

AB Based on the results of the authors screen identifying compds. and combinations of compds. having antiviral activity, the present invention features compns., methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments,

the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compds. that may be used to treat a viral disease.

CC 1-5 (Pharmacology)

IT Anti-AIDS agents

(vaccines, DNA; compns. and methods for treatment of viral diseases)

IT 139272-69-8, BMS 181184 139694-65-8, KNI 102 139893-43-9, Simvastatin acid ammonium salt 139981-26-3, MDL 74428 140942-13-8, Quinobene 141497-12-3 141752-91-2, Pegaldesleukin 141790-23-0, Fozivudine 141994-72-1, L 696474 142217-69-4, Entecavir 143070-01-3, PM 523 143205-42-9, NIM 811 143224-34-4, Telinavir 143338-12-9, BCH 10652 143390-74-3, BM 510836 143491-57-0, Emtricitabine 144113-82-6, NSC 627708 144141-97-9, A 80987 144189-66-2, 3-Nitrosobenzamide 144245-52-3, Fomivirsen 144779-91-9, R 87366 144875-48-9, Resiquimod 145258-61-3, Interferon β1 (human fibroblast protein moiety) 145417-33-0 145512-85-2, A 5021 145514-04-1, Amdoxovir 146426-40-6, Alvocidib 146739-86-8, S 2720 146794-68-5, SKF 108922 147127-20-6, Tenofovir 147318-81-8, KNI 272 147362-54-7, R 18893 147362-57-0, Loviride 147658-54-6, T 22 148314-61-8, LY 289612 148465-45-6, Crofelemer 148473-16-9, L 734005 148550-96-3, PD 144795 148692-46-0, U 88204E 148982-38-1, GR 137615 148998-94-1, Trecovirsen 149249-32-1, Neotripterifordin 149267-24-3, CGP 53820 149394-65-0, U 96988 149485-30-3, LY 73497 149486-68-0, HI 346 149488-17-5, Trovirdine 149572-31-6, Conocurvone 149754-11-0, CTC 96 149845-06-7, Saquinavir mesylate 149950-60-7, Emivirine 149950-61-8, GCA 186 150348-92-8, SB 206343 150378-17-9, Indinavir 150608-41-6, CGP 57813 150736-68-8, CGP 53437 150840-31-6, RP 70034 150840-75-8, RPR 103611 150915-41-6, Perospirone 150956-50-6, Canventol 151006-30-3, SR 3773 151356-08-0, Afovirsen 151867-81-1, DMP 323 152121-30-7, SB-202190 152835-17-1, RP 71955 152926-57-3, SPC 3 152929-04-9, XK 216 153021-65-9, SA 1042 153101-26-9, Regavirumab 153168-05-9, Pleconaril 153353-80-1, SB 205700 153436-53-4, Tyrphostin Ag 1478 153508-74-8, BCH 527 153873-88-2, 3-Episiastatin B 154212-56-3, Cosalane 154447-36-6, LY 294002 154482-69-6, SDZ 283471 154565-21-6, MER N5075A 154598-52-4, Efavirenz 154612-39-2, Palinavir 154612-58-5, BILA 2185 BS 155073-99-7, DG 35 155213-67-5, Ritonavir 155398-83-7, MDL 73669 155576-45-7, Tremacamra 156879-13-9 157589-64-5, MS 1060 157589-66-7, MS 888 157589-68-9, MS 1126 157726-04-0, BB 2116 157774-79-3, WIN 49569 158150-64-2, MEN 10690 158150-79-9, MEN 10979 158978-98-4, PMS 601 159074-53-0, Immunocal 159519-65-0, Enfuvirtide 159520-56-6, Z 100 159565-60-3, L 738372 159565-70-5, L 738872 159910-86-8, Droxinavir 159989-65-8, Nelfinavir mesylate 160492-05-7, L 735882 160495-86-3, SDZ 282870 160707-69-7, Apricitabine 160729-91-9, L 754394 160742-41-6, LB 71116 160799-71-3, SR 3775 161302-38-1, BMS 182193 161302-39-2, BMS 187071 161302-40-5, BMS 186318 161804-20-2, Benzamil hydrochloride 161814-49-9, Amprenavir 162054-18-4, AG 1284 162354-88-3, CGP 35269 162666-34-4, Flutimide 163222-33-1, Ezetimibe 163252-36-6, Clevudine 163451-80-7, Talviraline 163565-75-1, GE 20372A 163660-11-5, GE 20372B 164301-51-3, AXD 455 164416-13-1, Resobene 164514-52-7, SDZ 283053 165391-81-1, UC 68 165391-83-3, UC 42 165456-81-5 166089-33-4, BB 10010 166335-18-8, U 103017 166763-58-2, JCA 304 166981-11-9, CT 2576 167146-84-1, R 95288 167486-23-9, MDL 74695 167747-20-8, Felvizumab 167825-84-5, XR 835 169181-31-1, BL 1743 170020-61-8, FP 21399 170277-31-3, Infliximab 170447-93-5, BCX 140 171102-55-9, 739W94 171345-51-0, AR 177 171744-42-6, CI 1013 172256-89-2, UMJD 828 172929-12-3, Calcium spirulan 172998-57-1, UC 10 173046-01-0, MSC 127 173046-05-4, UC 70 173070-83-2, SO 324 173146-27-5, Denileukin diftitox 173261-21-7, A 98881 173720-57-5, GEM 132 174022-42-5, Bevirimat 174391-92-5, Mozenavir 174484-41-4, Tipranavir 174562-37-9, LB 71148 174562-62-0,

LB 71262 174885-43-9, SR 11335 175385-62-3, Lasinavir 175484-07-8, Quinoxapeptin A 175484-08-9, Quinoxapeptin B 175865-60-8, Valganciclovir 176161-24-3, Maribavir 176434-89-2, MDL 74968 178040-94-3, Opaviraline 178870-32-1, UC 781 178870-33-2, UC 82 178979-85-6, Capravirine 179402-61-0, GS 3333 179465-88-4, Y-ART-3 180302-29-8, DMP 850 181785-84-2, Elvucitabine 182997-40-6, NSC 667952 183856-26-0, SD 894 184294-78-8, AQ 148 184475-35-2, Gefitinib 184955-03-1, KNI 413 185220-03-5, PNU 142721 185243-69-0, Etanercept 185449-97-2, AHA 008 185829-22-5, MDIP 185902-61-8, LY 338387 185991-07-5, AMD 3465 185991-24-6, AMD 8664 186139-09-3, Trodusquemine 186380-62-1, CGP 64222 186415-82-7, ME 3738 186538-00-1, JE 2147 186673-22-3, DP 107 186829-19-6, CMV 423 187083-08-5, LB 71350 187227-45-8, GS 4071 187348-17-0, Edodekin alfa 187812-79-9, SRR SB3 187890-51-3, T 30695 188039-54-5, Palivizumab 188978-02-1, DMP 851 189185-60-2, Stachyflin 190013-89-9, A 74259 191594-64-6, CGP 75355 191617-90-0, FR 191512 192725-17-0, Lopinavir 193681-12-8, Alamifovir 195048-23-8, R 71762 195157-34-7, Valomaciclovir 195720-26-4, SJ 3366 196488-72-9, Ranpirnase 196618-13-0, Oseltamivir 197316-54-4, FR 198248 197365-88-1, CL 387626 197366-24-8, RFI 641 197840-96-3, Temacrazine 198153-51-4, Peginterferon alfa-2a 198821-22-6, Merimepodib 198904-01-7, CGP 75136 198904-13-1, CGP 75176 198904-31-3, Atazanavir 200496-39-5, QYL 438 202138-50-9, Tenofovir disoproxil fumarate 204866-62-6, MGN 3 206269-27-4, ICN 17261 206361-99-1, Darunavir 206362-00-7, TMC 126 206662-17-1, QM 96521 206662-19-3, QM 96639 207976-87-2, KM 043 208576-37-8, NSC 651016 209335-49-9, Feglymycin 210355-05-8, QYL 769 210355-14-9, QYL 685 211868-63-2, JBP 485 212370-72-4, HS 058 213972-23-7, DB 340 213982-93-5, WHI 05 213982-96-8, WHI 07 214287-88-4, DPC 961 214287-90-8, DPC 963 214287-99-7, DPC 083

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. and methods for treatment of viral diseases)

IT 214330-43-5 214841-85-7, ISIS 13312 215312-87-1, CGP 70726 215361-24-3, KNI 241 215647-85-1, Peginterferon alfa-2b 216863-66-0, L 756423 216884-02-5, CC 3052 217178-62-6, Stampidine 217817-99-7, AG 1350 218791-28-7, M 40401 219664-37-6, HI 240 220881-25-4, MTCH 24 220904-83-6, GW 5074 220984-26-9, AM 365 221122-06-1, MC 867 221447-99-0, A 160621 223537-30-2, Rupintrivir 223572-54-1, CRL 1072 223603-41-6, ISIS 14803 226225-77-0, KNI 684 226700-79-4, Fosamprenavir 227470-77-1, HB 19 227759-36-6, RD6 Y664 229005-80-5, TAK 779 229305-39-9, SCV 07 231957-54-3, MIV 150 232585-27-2, RB 2121 233254-24-5, Tomeglovir 233271-65-3, HI 236 240417-29-2, HI 445 240417-31-6, HI 280 240427-03-6, Papuamide A 244767-67-7, Dapivirine 246252-06-2, Motexafin gadolinium 251481-69-3, TNK 6123 251561-62-3, EM 2487 251562-00-2, Tifuvirtide 251922-77-7, L 731988 251963-74-3, L 708906 253199-06-3, NV 01 253678-35-2, DPC 082 254435-95-5, DEBIO-025 254750-02-2, IDN 6556 256376-24-6, Bay 41-2272 258340-15-7, HI 443 259745-74-9, BCTP 259793-96-9, T 705 259810-91-8, SR 41476 263006-09-3, TOFA 269055-15-4, Etravirine 280571-30-4, S 1360 282104-12-5, PD 178390 284040-61-5, HI 244 284661-68-3, DPC 681 284661-73-0, DPC 684 287096-87-1, Delmitide 287714-41-4, Rosuvastatin 300832-84-2, Ciluprevir 304897-80-1, WM 5 306293-41-4, SCH 350634 306296-47-9, Vicriviroc 313682-08-5, Brecanavir 314062-80-1, BTA 188 316350-99-9, AGT 1 317846-22-3, R 170591 319425-66-6, CF 1743 330600-85-6, Peramivir 332080-01-0, RD 30028 333994-00-6, TAK 220 335679-69-1, A 315675 336620-55-4, LY 366405 336620-57-6, LY 355455 339177-61-6, AD 439 339177-63-8, AD 519 339186-90-2, F 105 339526-68-0, MDX 240 339526-88-4, MEDI 488 345267-12-1, BCX 1827 345267-13-2, BCX 1923 345267-14-3, BCX 1898 351024-11-8, biological studies 352513-63-8, Semapimod

357263-13-9, BMS 806 370893-06-4, Ancriviroc 371226-86-7
376348-65-1, Maraviroc 377774-43-1, AR 132 379270-37-8, GS 7340
380886-95-3, Valtorcitabine 383198-58-1, PRO 542 383907-43-5, NSC
663284 391599-54-5, SF 950 394722-28-2, SCH 6 394729-90-9, PD 173606
394729-94-3, PD 177298 394730-00-8, PD 178392 394730-60-0, Boceprevir
402957-28-2, Telaprevir 410544-95-5, L 870810 439279-66-0, ME 609
441785-26-8, LB 80380 444805-28-1, CMX 001 452296-83-2, BMS 488043
461443-59-4, Aplaviroc 463941-20-0, HCV 371 472960-22-8, Albuferon
475650-36-3, ORI 9020 478410-84-3, AG 1859 497223-28-6, TAK 652
500287-72-9, Rilpivirine 554450-52-1, Krh 1120 558447-26-0
609817-23-4, EHT 899 625095-60-5, Pradefovir 632385-00-3, Heptazyme
640281-90-9, Valopicitabine 640725-71-9, NM-283 648904-28-3,
Bavituximab 656836-18-9, Civacir 656836-19-0, JTK 003 674782-26-4,
PRO 140 675184-41-5, VP 50406 675878-69-0, Omniferon 676128-63-5,
RSV 604 676271-69-5, SPL 7013 677010-34-3, Motavizumab 680188-33-4,
TNX 355 691852-58-1, HCV-796 697761-98-1, JTK 303 749886-87-1,
JSH-23 763903-67-9, Fosalvudine tidoxil 799292-77-6, Glamolec
817181-60-5, P 56 817204-33-4, PSI-6130 831228-17-2, HepeX-C
845621-43-4, ANA 971 845959-50-4, Mitoquinone 847442-84-6, A-837093
847453-47-8 848859-43-8, GPI 1485 848873-97-2, SRL 172 850876-88-9,
ITMN 191 851126-09-5, LY 180299 852337-16-7 857094-21-4, Sifuvirtide
862009-46-9, SPD 756 862009-84-5, GW 5950X 862009-87-8, R 944
864367-22-6, ITI 002 869572-92-9, SIGA 246 871038-72-1, MK 0518
871377-04-7, GEM 92 872851-09-7, DES 6 879480-40-7, C 2507
886995-06-8, GS 9005 908020-88-2, AVR 118 913185-43-0, WF 10
915407-80-6, GS 9160 918933-19-4 925701-76-4, INCB 9471 934014-96-7,
HCV 086 934409-11-7, NB 001 943540-08-7, KP 1461 943552-02-1, PC 515
957255-05-9, CPG 10101 1001913-09-2, R 1626 1001913-11-6, XTL 2125
1001913-12-7, R 7128 1001913-20-7, LB 84451 1001913-24-1, BIVN 401
1001913-33-2, NOV 205 1001913-35-4, EHC 18 1001913-38-7, EMZ 702
1001914-05-1, UT 231B 1001914-35-7, Virostat 1001914-70-0, KPE
02003002 1001914-90-4, AVI 4065 1004523-27-6, PPL 100 1004548-39-3,
AMZ 0026 1004548-56-4, HRG 214 1004550-34-8, PBS 119 1015078-81-5
1015078-87-1 1015078-88-2 1015078-89-3 1015078-90-6 1015078-91-7
1015078-92-8 1015078-93-9 1015078-94-0 1015078-96-2 1015078-97-3
1015078-98-4 1015078-99-5 1015079-00-1 1015079-01-2 1015079-02-3
1015079-03-4 1015079-04-5 1015079-05-6 1015079-07-8 1015079-08-9
1015079-09-0 1015079-10-3 1015079-11-4 1015079-14-7 1015079-15-8
1015079-17-0 1015079-18-1 1015079-19-2 1015079-20-5 1015079-21-6
1015079-22-7 1015079-23-8 1015079-24-9 1015079-25-0 1015079-26-1
1015079-27-2 1015079-28-3 1015079-29-4 1015079-30-7 1015079-31-8
1015079-32-9 1015079-33-0 1015079-34-1 1015079-35-2 1015079-36-3
1015079-37-4 1015079-38-5 1015079-39-6 1015079-40-9 1015079-41-0
1015079-42-1 1015079-43-2 1015079-44-3 1015079-45-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(compns. and methods for treatment of viral diseases)

IT 164301-51-3, AXD 455 352513-83-8, Semapimod
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(compns. and methods for treatment of viral diseases)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-
(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA
INDEX NAME)



RN 352513-83-8 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



L60 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:902874 HCAPLUS Full-text
DOCUMENT NUMBER: 143:248277
TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor
INVENTOR(S): Hamann, Lawrence H.; Bi, Yingzhi; Manfredi, Mark C.; Nirschl, Alexandra A.; Sutton, James C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077925	A1	20050825	WO 2005-US2834	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1718626 A1 20061108 EP 2005-712320 20050202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

PRIORITY APPLN. INFO.: US 2004-541869P P 20040204
WO 2005-US2834 W 20050202

OTHER SOURCE(S): CASREACT 143:248277; MARPAT 143:248277

GI


I


II


III

AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. Pharmaceutical compns. comprising I are disclosed.

IC ICM C07D285-06
ICS A61K031-433

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

IT AIDS (disease)
Acne
Adenoma

Aging, animal
Alopecia
Alzheimer's disease
Anemia (disease)
Anorexia
Anti-AIDS agents
Anti-Alzheimer's agents
Antiarthritics
Antidepressants
Antiobesity agents
Antitumor agents
Bladder, neoplasm
Brain, neoplasm
Burn
Cachexia
Cardiovascular agents
Chemotherapy
Cognition
Coma
Combination chemotherapy
Contraceptives
Cushing's syndrome
Dialysis
Eating disorders
Feeding
Heart, disease
Hirsutism
Homeostasis
Human
Hypothermia
Kidney, neoplasm
Lipodystrophy
Liver, neoplasm
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Multiple sclerosis
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Potassium channel openers
Preeclampsia
Prostate gland, neoplasm
Reperfusion
Seborrhea
Sexual disorders
Skin, neoplasm
Sleep
Sleep disorders
Spermatogenesis
Stress, biological
Transplant and Transplantation
Wound healing
(preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 50-02-2, Dexamethasone 50-07-7, Mitomycin 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-24-4, Thiotepa 52-53-9,

Verapamil 53-03-2, Prednisone 53-19-0, Mitotane 53-43-0, Dehydroepiandrosterone 53-86-1, Indomethacin 54-31-9, Furosemide 55-86-7, Nitrogen mustard 55-98-1, Busulfan 56-03-1, Biguanide 56-53-1 57-22-7, Vincristine 57-47-6, Physostigmine 57-83-0, Progestin, biological studies 58-22-0, Testosterone 58-32-2, Dipyridamole 58-54-8 58-55-9, Theophylline, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, biological studies 60-27-5, Creatinine 61-90-5, Leucine, biological studies 68-19-9, Vitamin B12 68-26-8, Vitamin A 71-58-9, Medroxyprogesterone acetate 73-48-3, Bendroflumethiazide 76-60-8, BCG 77-36-1, Chlorthalidone 91-33-8, Benzthiazide 122-09-8, Phentermine 127-07-1, Hydroxyurea 133-67-5, Trichlormethiazide 135-07-9 135-09-1, Hydroflumethiazide 147-94-4, Cytarabine 148-56-1, Flumethiazide 148-82-3, Melphalan 151-56-4, Ethylenimine, biological studies 154-42-7, Thioguanine 154-93-8, Carmustin 155-97-5, Pyridostigmine 302-79-4, Retinoic acid 303-98-0, Coenzyme Q-10 305-03-3, Chlorambucil 321-64-2, Tacrine 346-18-9, Polythiazide 378-44-9, BetaMethasone 396-01-0, Triamterene 439-14-5, Diazepam 541-15-1, Carnitine 595-33-5, Megestrol acetate 604-75-1, Oxazepam 625-08-1, β-Hydroxy-β-methylbutyric acid 630-60-4, Ouabain 645-05-6, Hexamethylmelamine 657-24-9, Metformin 671-16-9, Procarbazine 797-63-7, Levonorgestrel 846-49-1, Lorazepam 865-21-4, Vinblastine 1200-22-2, Lipoic acid 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1605-68-1, Taxane 2030-63-9, Clofazimine 2295-31-0, Thiazolidinedione 2609-46-3, Amiloride 2998-57-4, Estramustine 3056-17-5, Stavudine 3778-73-2, Ifosfamide 4205-90-7, Clonidine 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4375-07-9, Epipodophyllotoxin 5630-53-5, Tibolone 7439-95-4, Magnesium, biological studies 7440-09-7, Potassium, biological studies 7440-47-3, Chromium, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7481-89-2, Zalcitabine 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9002-64-6, Parathyroid hormone 9002-71-5, Thyrotropin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9015-68-3, L-Asparaginase 9041-93-4, Bleomycin sulfate 10238-21-8, Glyburide 10246-75-0, Hydroxyzine pamoate 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-20-3, Nitrosourea 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 15056-34-5, Triazene 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 16984-48-8, Fluoride, biological studies 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 24305-27-9, Trh 25316-40-9, Adriamycin 26027-38-3, Nonoxynol 9 26538-44-3, Zeranol 28395-03-1, Bumetanide 29094-61-9, Glipizide 29767-20-2, Teniposide 30516-87-1, Zidovudine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 35212-22-7, Ipriflavone 36085-73-1, B-HT920 36322-90-4, Piroxicam 36505-84-7, Buspirone 38304-91-5, Minoxidil 40180-04-9, Ticrynafen 41575-94-4, Carboplatin 42399-41-7, Diltiazem 51333-22-3, Budesonide 52205-73-9, Estramustine phosphate sodium 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54870-28-9, Meglitinide 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55294-15-0, Muzolimine 56180-94-0, Acarbose 57982-77-1, Buserelin 58095-31-1, Sulbenox 58957-92-9, Idarubicin 59729-33-8, Citalopram 59865-13-3, Cyclosporin A 61869-08-7, Paroxetine 62571-86-2, Captopril 66376-36-1, Alendronate 67763-96-6, IGF-1 67763-97-7, IGF-2 69655-05-6, Didanosine 73963-72-1, Cilostazol 75330-75-5, Lovastatin 75425-66-0, Saframycins 75847-73-3, Enalapril 76547-98-3, Lisinopril 79517-01-4, Octreotide acetate 79617-96-2, Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81872-10-8, Zofenopril 82924-03-6, Pentopril 83366-66-9,

Nefazodone 83435-66-9, Delapril 84449-90-1, Raloxifene 85441-61-8, Quinapril 87333-19-5, Ramipril 87616-84-0 88150-42-9, Amlodipine 88768-40-5 93479-97-1, Glimepiride 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98319-26-7, Finasteride 100286-90-6, Irinotecan hydrochloride 104987-11-3, FK-506 105462-24-6 106650-56-0, Sibutramine 107724-20-9, Eplerenone 110942-02-4, Aldesleukin 111025-46-8, Pioglitazone 111223-26-8, Ceranapril 113665-84-2, Clopidogrel 114798-26-4, Losartan 114977-28-5, Docetaxel 116644-53-2, Mibefradil 116680-01-4, CellCept 117091-64-2, Etoposide phosphate 120014-06-4, Donepezil 121181-53-1, Filgrastim 122111-03-9, Gemcitabine hydrochloride 122320-73-4, Rosiglitazone 123441-03-2, Exelon 123774-72-1, Sargramostim 123948-87-8, Topotecan 125317-39-7, Vinorelbine tartrate 127779-20-8, Saquinavir 129318-43-0, MK-217 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 135062-02-1, Repaglinide 137109-78-5, OR1384 137862-53-4, Valsartan 138402-11-6, Irbesartan 139755-83-2, Sildenafil 141626-36-0, Dronedarone 141750-63-2, Nisvastatin 143443-90-7, Ifetroban 143653-53-6, Abciximab 144494-65-5, Tirofiban 147030-48-6, KB-130015 147191-91-1, Priliximab 147511-69-1, Itavastatin 149845-06-7, Saquinavir mesylate 150322-43-3, CS-747 155213-67-5, Ritonavir 157810-81-6, Indinavir sulfate 158861-67-7, Ghrp-2 159183-92-3, L750355 159752-10-0, MK-677 160135-92-2, Gemopatrilat 162011-90-7, Vioxx 164301-51-3, CNI-1493 167305-00-2, Omapatrilat 169590-42-5, Celebrex 170277-31-3, Infliximab

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 164301-51-3, CNI-1493

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:216606 HCAPLUS Full-text

DOCUMENT NUMBER: 142:292452
TITLE: Compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on differential gene or protein expression
INVENTOR(S): Pasricha, Pankaj; Shenoy, Mohan; Winston, John
PATENT ASSIGNEE(S): Cytokine Pharmasciences, Inc., USA
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020902	A2	20050310	WO 2004-US27356	20040823
WO 2005020902	A3	20060727		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050130189	A1	20050616	US 2004-923035	20040823

PRIORITY APPLN. INFO.: US 2003-496716P P 20030821

AB Compns. and methods for diagnosing and treating chronic visceral hypersensitivity (CVH) and CVH-associated disorders, such as irritable bowel syndrome, are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the transcribed polynucleotides and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. The examples discuss the effects of acetic acid sensitization and CNI1493 treatment on the colon and S1 dorsal root ganglia in a rat model of visceral hypersensitivity. Gene expression profiles associated with these treatments are presented, and rat CVH-related genes and polypeptides are identified.

IC ICM A61K
CC 3-1 (Biochemical Genetics)
Section cross-reference(s): 1, 6, 14, 63
IT DNA
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cas-Br-M (murine) ectopic retroviral transforming sequence b; compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)
IT Drugs
Human
Protein expression profiles, animal
Rat endogenous retrovirus
(compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)

IT 79-17-4, Hydrazinecarboximidamide 164301-51-3, CNI1493
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic composition comprising; compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)
IT 164301-51-3, CNI1493
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic composition comprising; compns. and methods for treating and diagnosing chronic visceral hypersensitivity and irritable bowel syndrome, based on gene or protein expression profiles)
RN 164301-51-3 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

L60 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:26375 HCAPLUS Full-text
DOCUMENT NUMBER: 142:211498
TITLE: Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy
AUTHOR(S): Hauber, Ilona; Bevec, Dorian; Heukeshoven, Jochen; Kraetzer, Friedrich; Horn, Florian; Choidas, Axel; Harrer, Thomas; Hauber, Joachim
CORPORATE SOURCE: Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany
SOURCE: Journal of Clinical Investigation (2005), 115(1), 76-85
CODEN: JCINAO; ISSN: 0021-9738
PUBLISHER: American Society for Clinical Investigation
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The introduction of highly active antiretroviral therapy (HAART) has significantly decreased morbidity and mortality among patients infected with HIV-1. However, HIV-1 can acquire resistance against all currently available antiretroviral drugs targeting viral reverse transcriptase, protease, and gp41. Moreover, in a growing number of patients, the development of multidrug-resistant viruses compromises HAART efficacy and limits therapeutic options. Therefore, it is an ongoing task to develop new drugs and to identify new targets for antiretroviral therapy. Here, we identified the guanylhydrazone CNI-1493 as an efficient inhibitor of human deoxyhypusine synthase (DHS). By inhibiting DHS, this compound suppresses hypusine

formation and, thereby, activation of eukaryotic initiation factor 5A (eIF-5A), a cellular cofactor of the HIV-1 Rev regulatory protein. We demonstrate that inhibition of DHS by CNI-1493 or RNA interference efficiently suppressed the retroviral replication cycle in cell culture and primary cells. We show that CNI-1493 inhibits replication of macrophage- and T cell-tropic laboratory strains, clin. isolates, and viral strains with high-level resistance to inhibitors of viral protease and reverse transcriptase. Moreover, no measurable drug-induced adverse effects on cell cycle transition, apoptosis, and general cytotoxicity were observed Therefore, human DHS represents a novel and promising drug target for the development of advanced antiretroviral therapies, particularly for the inhibition of multidrug-resistant viruses.

CC 1-5 (Pharmacology)

ST deoxyhypusine synthase antiretroviral HIV1 CNI1493

IT Translation initiation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eIF-5A; identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy)

IT Anti-AIDS agents
Human
Human immunodeficiency virus 1
Multidrug resistance
(identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy)

IT 164301-51-3, CNI-1493
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy)

IT 127069-31-2, Deoxyhypusine synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy)

IT 164301-51-3, CNI-1493
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:41229 HCAPLUS Full-text
DOCUMENT NUMBER: 140:105266
TITLE: Boroproline compound combination therapy for various diseases
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004661	A2	20040115	WO 2003-US21547	20030709
WO 2004004661	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491474	A1	20040115	CA 2003-2491474	20030709
AU 2003248921	A1	20040123	AU 2003-248921	20030709
US 20040077601	A1	20040422	US 2003-616694	20030709
US 20050084490	A1	20050421	US 2003-616409	20030709
EP 1578362	A2	20050928	EP 2003-763433	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506442	T	20060223	JP 2004-562639	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709
IN 2005KN00152	A	20051007	IN 2005-KN152	20050208

PRIORITY APPLN. INFO.:	US 2002-394856P	P	20020709
	US 2002-414978P	P	20021001
	US 2003-466435P	P	20030428
	WO 2003-US21547	W	20030709

GI



I

AB A method is provided for treating subjects with combination therapy including compds. of Formula I (wherein m is an integer between 0 and 10, inclusive; A

and A1 may be L- or D-amino acid residues, the C bonded to B is in the L-configuration, and each X1 and X2 is, independently, a hydroxy group or a group capable of being hydrolyzed to a hydroxy group in aqueous solution at physiol. pH). It was surprisingly discovered that this combination enhanced the efficacy of both agents, and that administration of Formula I compds. induced cytokine and chemokine production in vivo. The combinations can be used to enhanced ADCC, stimulate immune responses and /or patient and treat certain disorders. The invention also relates to kits and compns. relating to such combinations.

IC ICM A61K

CC 1-7 (Pharmacology)

IT Acute lymphocytic leukemia
Acute myeloid leukemia
Anti-AIDS Agents
Antibacterial agents
Antimalarials
Antitumor agents
Antiviral agents
Biliary tract, neoplasm
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Cardiovascular agents
Cardiovascular system, disease
Central nervous system, neoplasm
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Digestive tract, neoplasm
Drug delivery systems
Esophagus, neoplasm
Eye, neoplasm
Fungicides
Head and Neck
Head and Neck, neoplasm
Hepatitis
Hodgkin's disease
Human
Immunostimulants
Immunostimulation
Infection
Influenza
Kidney, neoplasm
Larynx, neoplasm
Leprosy
Leukemia
Liver, neoplasm
Lymphoma
Mammary gland, neoplasm
Melanoma
Mouth, neoplasm
Multiple myeloma
Multiple sclerosis
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Parasiticides
Prostate gland, neoplasm
Respiratory system, neoplasm
Sarcoma
Skin, neoplasm

Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Tinea (skin disease)
Trypanosomicides
Tuberculosis
Tuberculostatics
Urinary system, neoplasm
Uterus, neoplasm
Vaccines
(boroproline compound combination therapy for various diseases)

IT Actinomyces
Adenoviridae
Bacteroides
Borrelia
Campylobacter
Citrobacter
Clostridium difficile
Corynebacterium
Cytomegalovirus
Echinococcus
Enterobacter
Escherichia coli
Fasciola
Gardnerella
Haemophilus
Helicobacter pylori
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Histoplasma capsulatum
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human papillomavirus
Hymenolepis
Influenza A virus
Klebsiella
Legionella
Listeria
Madurella mycetomatis
Monkeypox virus
Necator americanus
Neisseria
Nocardia
Paragonimus
Pasteurella
Plasmodium (malarial genus)
Pneumocystis
Proteus (bacterium)
Pseudallescheria
Pseudomonas
Respiratory syncytial virus
Rotavirus
Salmonella
Shigella
Spirillum
Spirochaeta

Staphylococcus
Streptobacillus
Streptococcus
Streptococcus pneumoniae
Taenia
Treponema
Trichomonas vaginalis
Trichuris trichiura
Trypanosoma brucei
Trypanosoma cruzi
(infection; boroproline compound combination therapy for various diseases)

IT 3424-98-4 4428-95-9 9002-10-2, Tyrosinase 9035-74-9, Glycogen phosphorylase 19545-26-7, KY 12420 19600-01-2, GM2 ganglioside 31362-50-2, Bombesin 36791-04-5, Ribavirin 53678-77-6, Muramyl dipeptide 59277-89-3, Acyclovir 62010-37-1, Ganglioside GD3 62010-37-1D, Ganglioside GD3, mimic 65988-71-8, Ganglioside GD2 69521-94-4, Thymosin α-1 80043-53-4, Gastrin-releasing peptide 82410-32-0, Ganciclovir 82707-54-8, Neprilysin 92562-88-4 104227-87-4, Famciclovir 127464-60-2, Vascular endothelial growth factor 127759-89-1, Lobucavir 134678-17-4, Lamivudine 139442-47-0, LFM-A 12 142217-69-4, Entecavir 142340-99-6, Adefovir dipivoxil 143491-57-0, Emtricitabine 147014-97-9, Cdk4 kinase 149565-66-2, Kallikrein 6 149682-77-9 152121-44-3 152923-56-3, Daclizumab 156586-89-9, Panorex 163252-36-6, Clevudine 164301-51-3, CNI-1493 167869-21-8, PD98059 170277-31-3, Infliximab 174722-31-7, Rituxan 180288-69-1, Herceptin 183319-69-9, OSI-774 184475-35-2, Iressa 185243-69-0, Etanercept 188039-54-5, Palivizumab 192391-48-3, Bexxar 205923-56-4, IMC-C225 206181-63-7, Zevalin 208921-02-2, Tositumomab 211555-05-4, WHI-P97 213327-37-8, Oregovomab 216503-57-0, Alemtuzumab 216503-57-0, Campath 216503-58-1, BEC2 216974-75-3, Avastin 220578-59-6, Mylotarg 334993-12-3, Kallikrein 10 339150-51-5, CeaVac 339150-82-2, LymphoCide 339151-95-0, MDX-22 339151-96-1, MDX-447 339152-71-5, MDX-210 339286-23-6, Gliomab-H 339286-24-7, GNI-250 339526-06-6, B3 (Antibody) 339526-30-6, MDX-220 478159-73-8, BR 96 645405-72-7 645409-76-3 645416-54-2, AG 1458 646031-42-7, Celogovab 646032-07-7, Zamyl
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(boroproline compound combination therapy for various diseases)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(boroproline compound combination therapy for various diseases)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



L60 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:41226 HCAPLUS Full-text
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491466	A1	20040115	CA 2003-2491466	20030709
AU 2003265264	A1	20040123	AU 2003-265264	20030709
US 20040077601	A1	20040422	US 2003-616694	20030709
US 20050084490	A1	20050421	US 2003-616409	20030709
EP 1578434	A2	20050928	EP 2003-763380	20030709
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006507352	T	20060302	JP 2004-562634	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709
CN 1826129	A	20060830	CN 2003-821281	20030709
IN 2005KN00151	A	20050916	IN 2005-KN151	20050208
PRIORITY APPLN. INFO.:			US 2002-394856P P	20020709
			US 2002-414978P P	20021001

US 2003-466435P P 20030428
WO 2003-US21405 W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptidyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IC ICM A61K

CC 1-12 (Pharmacology)
Section cross-reference(s): 15

IT Actinomyces
Adenoviridae
Bacteroides
Borrelia
Campylobacter
Citrobacter
Clostridium difficile
Corynebacterium
Cytomegalovirus
Echinococcus
Enterobacter
Escherichia coli
Fasciola
Gardnerella
Haemophilus
Helicobacter pylori
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human papillomavirus
Hymenolepis
Klebsiella
Legionella
Listeria
Monkeypox virus
Necator americanus
Neisseria
Nocardia
Paragonimus
Pasteurella
Pneumocystis
Proteus (bacterium)
Pseudomonas
Respiratory syncytial virus
Rotavirus
Salmonella
Shigella
Spirillum
Spirochaeta
Streptobacillus
Streptococcus

Streptococcus pneumoniae
Taenia
Treponema
Trichomonas vaginalis
Trichuris trichiura
Trypanosoma brucei
Trypanosoma cruzi
(infection; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 63527-52-6, Cefotaxime 63585-09-1, Foscarnet sodium 64211-46-7, Oxiconazole nitrate 64221-86-9, Imipenem 64221-86-9D, Imipenem, derivs. 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil 64872-77-1, Butoconazole nitrate 64952-97-2, Moxalactam 65025-62-9, (-)-Soulattrolide 65052-63-3, Cefetamet 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65473-14-5, Naftifine hydrochloride 65899-73-2, Tioconazole 66148-78-5, Temocillin 66309-69-1, Cefotiam hydrochloride 66887-96-5, Propikacin 67337-44-4, Sarmoxicillin 67915-31-5, Terconazole 68401-82-1, Ceftizoxime sodium 68693-30-1, Somantadine hydrochloride 68902-57-8, Metioprim 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69198-10-3, Metronidazole hydrochloride 69402-03-5, Piridicillin sodium 69521-94-4, Thymosin α-1 69655-05-6, Didanosine 69657-51-8, Acyclovir sodium 69712-56-7, Cefotetan 69756-53-2, Halofantrine 70052-12-9, Eflornithine 70288-86-7, Ivermectin 70458-92-3, Pefloxacin 70458-95-6, Pefloxacin mesylate 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 71002-10-3, Vidarabine sodium phosphate 71420-79-6 72275-67-3, Astromicin sulfate 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73334-05-1, Metronidazole phosphate 73384-59-5, Ceftriaxone 73514-87-1, Fosarilate 73816-42-9, Meclocycline sulfosalicylate 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium 74578-69-1, Ceftriaxone sodium 74682-62-5, Ticarcillin monosodium 74849-93-7, Cefpiramide sodium 75738-58-8, Cefmenoxime hydrochloride 76168-82-6, Ramoplanin 76470-66-1, Loracarbef 76497-13-7, Sultamicillin 76610-84-9, Cefbuperazone 77146-42-0, Chlorhexidine phosphanilate 77181-69-2, Sorivudine 78040-85-4, Coumermycin 78110-38-0, Aztreonam 78186-33-1, Fumoxicillin 78613-35-1, Amorolfine 78822-40-9, Pirlimycin hydrochloride 78964-85-9, Fosfomycin tromethamine 79350-37-1, Cefixime 79404-91-4, Cilofungin 79660-72-3, Fleroxacin 80168-44-1, Zinoconazole hydrochloride 80214-83-1, Roxithromycin 80621-81-4, Rifaximin 80883-55-2, Enviradene 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83038-87-3, Doxycycline fosfatex 83200-96-8D, Carbapenem, derivs. 83905-01-5, Azithromycin 84408-37-7, Desciclovir 84625-61-6, Itraconazole 84880-03-5, Cefpimizole 85287-61-2, Cefpimizole sodium 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 86832-68-0, Carumonam sodium 87239-81-4, Cefpodoxime proxetil 87495-31-6, Disoxaril 87806-31-3, Porfimer sodium 88036-80-0, Amifloxacin mesylate 88040-23-7, Cefepime 90849-08-4, Oximonam sodium 90850-05-8, Gloximonam 90898-90-1, Oximonam 91161-71-6, Terbinafine 91618-36-9, Ibafloxacin 91832-40-5, Cefdinir 92562-88-4 92665-29-7, Cefprozil 93107-08-5, Ciprofloxacin hydrochloride 94088-85-4, Doxycycline calcium 94168-98-6, Rifametane 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96128-89-1, Erythromycin acistrate 97519-39-6, Ceftibuten 97673-66-0, Trospectomycin sulfate 97682-44-5, Irinotecan 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin hydrochloride 98753-19-6, Cefpirome sulfate 100234-70-6, Resorcinomycin A 100490-36-6, Tosufloxacin 100680-33-9, Cefuroxime pivoxetil 101828-21-1, Butenafine 102426-96-0, Paldimycin 103060-53-3, Daptomycin 104227-87-4, Famciclovir 104456-95-3,

Cisconazole 105784-61-0, Temafloxacin hydrochloride 105956-99-8, Clinafloxacin hydrochloride 106941-25-7, Adefovir 107648-80-6, Cefepime hydrochloride 107910-75-8, Ganciclovir sodium 108319-06-8, Temafloxacin 110042-95-0, Acemannan 110588-57-3, Saperconazole 110871-86-8, Sparfloxacin 110942-02-4, Aldesleukin 112362-50-2, Dalfopristin 113102-19-5, Rifamexil 113852-37-2, Cidofovir 114394-67-1, Lomefloxacin mesylate 114977-28-5, Taxotere 117091-64-2, Etoposide phosphate 117211-03-7, Cefetecol 119413-54-6, Topotecan hydrochloride 120138-50-3, Quinupristin 120410-24-4, Biapenem 120788-07-0, Sulopenem 122111-03-9, Gemcitabine hydrochloride 124436-59-5, Pirodavir 124832-27-5, Valacyclovir hydrochloride 125317-39-7, Vinorelbine tartrate 127464-60-2, Vascular endothelial growth factor 127759-89-1, Lobucavir 127779-20-8, Saquinavir 127785-64-2, Basifungin 129618-40-2, Nevirapine 130167-69-0, Pegaspargase 132210-43-6, Cipamfylline 134678-17-4, Lamivudine 136817-59-9, Delavirdine 137487-62-8, Alvircept sudotox 138540-32-6, Atevirdine mesylate 139442-47-0, LFM-A 12 141611-76-9, Sanfetrinem sodium 142217-69-4, Entecavir 142340-99-6, Adefovir dipivoxil 142632-32-4, (+)Calanolide A 143491-57-0, Emtricitabine 147221-93-0, Delavirdine mesylate 149845-06-7, Saquinavir mesylate 150378-17-9, Indinavir 150572-30-8 151581-81-6, Pradimicin 152121-44-3 152923-56-3, Daclizumab 154598-52-4, Efavirenz 155213-67-5, Ritonavir 156586-89-9, Panorex 159989-64-7, Nelfinavir 163252-36-6, Clevudine 163661-45-8, (-)-Calanolide A 164301-51-3, CNI-1493 167869-21-8, PD98059 170277-31-3, Infliximab 174722-31-7, Rituxan 179463-17-3, MK 991 180288-69-1, Herceptin 183319-69-9, Tarceva 184475-35-2, Iressa 185243-69-0, Etanercept 187029-72-7, (-)-7,8-Dihydrosoulattrolide 188039-54-5, Palivizumab 205923-56-4, IMC-C225 206181-63-7, Zevalin 208538-73-2, FK 463 208921-02-2, Tositumomab 211555-05-4, WHI-P97 213327-37-8, Oregovomab 216503-57-0, Campath 216503-58-1, Mitumomab 216974-75-3, Avastin 220578-59-6, Mylotarg 339150-51-5, CeaVac 339150-82-2, LymphoCide 339151-95-0, MDX-22 339151-96-1, MDX-447 339152-71-5, MDX-210 339286-23-6, Gliomab-H 339286-24-7, GNI-250 339526-30-6, MDX-220 478159-64-7, 2C3 645405-72-7 645405-73-8 645416-54-2, AG 1458 645417-10-3, UK 292 645417-21-6, BAY 38-9502 646031-42-7, Celogovab 646032-07-7, Zamyl
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 164301-51-3, CNI-1493
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

RN 164301-51-3 HCAPLUS

CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:742360 HCAPLUS Full-text
DOCUMENT NUMBER: 142:235280
TITLE: Screening assay for the identification of deoxyhypusine synthase inhibitors
AUTHOR(S): Sommer, Marc-Nicola; Bevec, Dorian; Klebl, Bert; Flicke, Birgit; Hoelscher, Kerstin; Freudenreich, Tatjana; Hauber, Ilona; Hauber, Joachim; Mett, Helmut
CORPORATE SOURCE: Axxima Pharmaceuticals AG, Munich, D-81377, Germany
SOURCE: Journal of Biomolecular Screening (2004), 9(5), 434-438
CODEN: JBISF3; ISSN: 1087-0571
PUBLISHER: Sage Publications
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The 1st step in the posttranslational hypusine [Nε-(4-amino-2-hydroxybutyl)lysine] modification of eukaryotic translation initiation factor 5A (eIF5A) is catalyzed by deoxyhypusine synthase (DHS). The eIF5A intermediate is subsequently hydroxylated by deoxyhypusine hydroxylase (DHH), thereby converting the eIF5A precursor into a biol. active protein. Depletion of eIF5A causes inhibition of cell growth, and the identification of eIF5A as a cofactor of the HIV Rev protein turns this host protein and therefore DHS into an interesting target for drugs against abnormal cell growth and/or HIV replication. The authors developed a 96-well format DHS assay applicable for the screening of DHS inhibitors. Using this assay, they demonstrate DHS inhibition by AXD455 (Semapimod, CNI-1493). This assay represents a powerful tool for the identification of new DHS inhibitors with potency against cancer and HIV.

CC 7-1 (Enzymes)
Section cross-reference(s): 1, 9, 10, 14

IT Drug screening
Human immunodeficiency virus 1
(screening assay for identification of deoxyhypusine synthase inhibitors)

IT 164301-51-3, CNI-1493
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(screening assay for identification of deoxyhypusine synthase inhibitors)

IT 164301-51-3, CNI-1493

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(screening assay for identification of deoxyhypusine synthase inhibitors)
RN 164301-51-3 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, hydrochloride (1:4) (CA INDEX NAME)



●4 HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:581691 HCAPLUS Full-text
DOCUMENT NUMBER: 135:162484
TITLE: Aromatic guanylhydrazones and their therapeutic use, especially for prophylaxis and treatment of bacterially or virally caused diseases and infections
INVENTOR(S): Bevec, Dorian; Hauber, Joachim; Obert, Sabine; Keri, Gyorgy; Orfi, Laszlo; Szekely, Istvan; Choidas, Axel; Bacher, Gerald
PATENT ASSIGNEE(S): Axxima Pharmaceuticals A.-G., Germany
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056553	A2	20010809	WO 2001-EP1126	20010202
WO 2001056553	A3	20020328		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1255541	A2	20021113	EP 2001-911580	20010202
EP 1255541	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 308982	T	20051115	AT 2001-911580	20010202
ES 2250363	T3	20060416	ES 2001-911580	20010202
US 20030203969	A1	20031030	US 2003-182752	20030107
US 20050171176	A1	20050804	US 2005-52325	20050207
PRIORITY APPLN. INFO.:			EP 2000-102050 A	20000202
			US 2000-179795P P	20000202
			WO 2001-EP1126 W	20010202
			US 2003-182752 A3	20030107

OTHER SOURCE(S): MARPAT 135:162484

AB The present invention provides aromatic guanylhydrazone compds. and their use as pharmaceutically active agents, especially for prophylaxis and treatment of virally caused diseases and infections, including opportunistic infections. The guanylhydrazone compds. are also useful as inhibitors of deoxyhypusine synthase and as inhibitors for nuclear export in infectious diseases and may be used to regulate bacterially induced TNF-α production Furthermore, the aromatic guanylhydrazones exhibit antibacterial activity against Gram-pos. and Gram-neg. bacteria and can be regarded as a novel class of antibiotics. In addition, methods for prophylaxis and treatment of virally or bacterially induced infections and diseases are disclosed, together with pharmaceutical compns. useful within the methods containing at least one aromatic guanylhydrazone of the invention as active ingredient.

IC ICM A61K031-00

CC 1-5 (Pharmacology)
Section cross-reference(s): 63

IT Human immunodeficiency virus
(T-cell- or macrophage-tropic; aromatic guanylhydrazones and therapeutic use, especially for prophylaxis and treatment of bacterially or virally caused diseases and infections)

IT Acinetobacter baumannii
Acinetobacter calcoaceticus
Aeromonas
Anti-infective agents
Antibacterial agents
Antibiotics
Antiviral agents
Apoptosis
Bacteroides
Bartonella bacilliformis
Bartonella henselae
Blood-brain barrier
Borrelia
Bovine immunodeficiency virus
Bovine leukemia virus
Brucella
Burkholderia cepacia
Calymmatobacterium granulomatis
Campylobacter fetus
Campylobacter jejuni
Caprine arthritis encephalitis virus
Cardiobacterium hominis
Cell cycle
Chlamydia trachomatis
Cholera
Citrobacter
Drug delivery systems
Drug interactions

Drug resistance
Dysentery
Eikenella corrodens
Encephalitis
Enterobacter
Equine infectious anemia virus
Escherichia coli
Feline immunodeficiency virus
Fusobacterium
Gardnerella vaginalis
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Ground squirrel hepatitis B virus
Hepadnaviridae
Hepatitis B virus
Human T-lymphotropic virus 1
Human T-lymphotropic virus 2
Human adenovirus
Human herpesvirus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 5
Human herpesvirus 8
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Influenza virus
Klebsiella
Lentivirus
Leptospira interrogans
Moraxella catarrhalis
Morganella (bacterium)
Paramyxovirus
Porphyromonas
Prevotella
Proteus (bacterium)
Providencia
Pseudomonas aeruginosa
RNA splicing
Respiratory syncytial virus
Retroviridae
Rickettsia prowazeki
Salmonella enterica
Serratia
Shigella
Simian immunodeficiency virus
Stenotrophomonas maltophilia
Syphilis
Toxoplasma
Treponema pallidum
Vibrio cholerae
Woodchuck hepatitis virus
Yersinia enterocolitica
Yersinia pestis
(aromatic guanylhydrazones and therapeutic use, especially for prophylaxis and
treatment of bacterially or virally caused diseases and infections)
IT Retroviridae
(oncoretrovirus; aromatic guanylhydrazones and therapeutic use, especially

for
prophylaxis and treatment of bacterially or virally caused diseases and infections)

IT 169764-84-5 174423-62-2 174423-64-4
352513-82-7 352513-83-8 352513-84-9
352513-85-0 352513-86-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aromatic guanylhydrazones and therapeutic use, especially for prophylaxis and
treatment of bacterially or virally caused diseases and infections)

IT 169764-84-5 174423-62-2 174423-64-4
352513-82-7 352513-83-8 352513-84-9
352513-85-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aromatic guanylhydrazones and therapeutic use, especially for prophylaxis and
treatment of bacterially or virally caused diseases and infections)

RN 169764-84-5 HCAPLUS
CN Pentanediamide, N1,N5-bis[3-[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



RN 174423-62-2 HCAPLUS
CN Hexanediamide, N1,N6-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



RN 174423-64-4 HCAPLUS
CN Hydrazinecarboximidamide, 2,2'-[[5-[[[[4-[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]amino]carbonyl]amino]-1,3-phenylene]diethylidyne]bis- (CA INDEX NAME)



RN 352513-82-7 HCAPLUS
CN Pentanediamide, N1,N5-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



RN 352513-83-8 HCAPLUS
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



RN 352513-84-9 HCAPLUS
CN Butanediamide, N1,N4-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



RN 352513-85-0 HCAPLUS
CN Heptanediamide, N1,N7-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 12 OF 29 USPATFULL on STN

ACCESSION NUMBER:	2008:298863 USPATFULL Full-text
TITLE:	Guanylhydrazone Salts, Compositions, Processes of Making, and Methods of Using
INVENTOR(S):	Sielecki-Dzurdz, Thais M., Kennett Square, PA, UNITED STATES
PATENT ASSIGNEE(S):	Cytokine PharmaSciences, Inc., King of Prussia, PA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080262090	A1	20081023
APPLICATION INFO.:	US 2007-931738	A1	20071031 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2007-766794, filed on 22 Jun 2007, PENDING Continuation of Ser. No. US 2005-165255, filed on 24 Jun 2005, Pat. No. US 7244765		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-582532P	20040625 (60)
	US 2004-601992P	20040817 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Law Office of John K. Pike, PLLC, 2121 Eisenhower Avenue, Suite 200, Alexandria, VA, 22314, US	

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 3032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 872830-77-8P 872830-78-9P 872830-79-0P
872830-80-3P 872830-81-4P
(compns. containing guanylhydrazone salts)
RN 872830-77-8 USPATFULL
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 352513-83-8
CMF C34 H52 N18 O2



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 872830-78-9 USPATFULL
CN L-Glutamic acid, compd. with N,N'-bis[3,5-bis[1-[(aminoiminomethyl)hydrazono]ethyl]phenyl]decanediamide (9CI) (CA INDEX NAME)

CM 1

CRN 352513-83-8
CMF C34 H52 N18 O2



CM 2

CRN 56-86-0
CMF C5 H9 N O4
CDES 5:L

Absolute stereochemistry.



RN 872830-79-0 USPATFULL
CN Propanoic acid, 2-hydroxy-, (2S)-, compd. with N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]decanediamide (1:?) (CA INDEX NAME)

CM 1

CRN 352513-83-8
CMF C34 H52 N18 O2



CM 2

CRN 79-33-4
CMF C3 H6 O3

Absolute stereochemistry. Rotation (+).

RN 872830-80-3 USPATFULL
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 352513-83-8
CMF C34 H52 N18 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 872830-81-4 USPATFULL
CN Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 352513-83-8
CMF C34 H52 N18 O2



CM 2

CRN 7664-93-9
CMF H2 O4 S

FILE 'HOME' ENTERED AT 09:51:01 ON 07 APR 2009

SEARCH HISTORY

```
=> d stat que l12;d his nofile
L10             STR
```



```
VAR G1=10/14/16/18/24/29/35/39
VAR G2=43/54/57/59/46
VAR G3=H/ME
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   2 13 14 15 16 17 20 26 32 36 40 58 60 61 62 63
GGCAT   IS MCY  LOC  UNS  AT   2
GGCAT   IS MCY  LOC  UNS  AT  13
GGCAT   IS MCY  LOC  UNS  AT  14
GGCAT   IS MCY  LOC  UNS  AT  15
GGCAT   IS MCY  LOQ  UNS  AT  16
GGCAT   IS MCY  LOC  UNS  AT  17
GGCAT   IS MCY  LOC  UNS  AT  58
GGCAT   IS MCY  LOC  UNS  AT  60
GGCAT   IS MCY  LOC  UNS  AT  61
GGCAT   IS MCY  LOC  UNS  AT  62
GGCAT   IS MCY  LOC  UNS  AT  63
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E5 C  E1 N  AT  16

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  57

STEREO ATTRIBUTES: NONE
L12         228 SEA FILE=REGISTRY SSS FUL L10

100.0% PROCESSED   22029 ITERATIONS                      228 ANSWERS
SEARCH TIME: 00.00.01



     (FILE 'HOME' ENTERED AT 09:06:13 ON 07 APR 2009)
```

```
     FILE 'CAPLUS' ENTERED AT 09:06:26 ON 07 APR 2009
                  E US2003-619426/APPS
L1             1 SEA SPE=ON  ABB=ON  US2003-619426/AP
                  D SCAN
                  SEL RN

     FILE 'REGISTRY' ENTERED AT 09:07:03 ON 07 APR 2009
L2             4 SEA SPE=ON  ABB=ON  (164301-51-3/BI OR 165245-96-5/BI OR
                  208197-81-3/BI OR 208197-82-4/BI)
                  D SCAN
L3                STR
L4            50 SEA SSS SAM L3

     FILE 'STNGUIDE' ENTERED AT 09:12:07 ON 07 APR 2009

     FILE 'REGISTRY' ENTERED AT 09:19:55 ON 07 APR 2009
L5                STR
L6             0 SEA SSS SAM L5 AND L3
L7             0 SEA SSS SAM L5
                  D QUE
                  D SCAN L2
L8             1 SEA SSS FUL L5
                  SAVE TEMP L8 JAG426FULL/A
L9             0 SEA SPE=ON  ABB=ON  L8 AND L2
                  D QUE L8
L10               STR L5
L11            8 SEA SSS SAM L10
                  D SCAN
L12          228 SEA SSS FUL L10
                  SAVE TEMP L12 JAG426FULL/A

     FILE 'CAPLUS' ENTERED AT 09:38:33 ON 07 APR 2009
L13          164 SEA SPE=ON  ABB=ON  L12
L14          243 SEA SPE=ON  ABB=ON  TRACEY K?/AU
L15         1949 SEA SPE=ON  ABB=ON  COHEN P?/AU
L16           99 SEA SPE=ON  ABB=ON  BUKRINSKY M?/AU
L17           23 SEA SPE=ON  ABB=ON  SCHMIDTMAYEROVA H?/AU
L18           37 SEA SPE=ON  ABB=ON  (L1 OR L14 OR L15 OR L16 OR L17) AND L13
                  E HIV+ALL/CT
                  E E2+ALL

     FILE 'HCAPLUS' ENTERED AT 09:40:24 ON 07 APR 2009
L19            1 SEA SPE=ON  ABB=ON  US2003-619426/AP
L20          243 SEA SPE=ON  ABB=ON  TRACEY K?/AU
L21         1949 SEA SPE=ON  ABB=ON  COHEN P?/AU
L22           99 SEA SPE=ON  ABB=ON  BUKRINSKY M?/AU
L23           23 SEA SPE=ON  ABB=ON  SCHMIDTMAYEROVA H?/AU
L24          164 SEA SPE=ON  ABB=ON  L12
L25        64502 SEA SPE=ON  ABB=ON  HUMAN IMMUNODEFICIENCY VIRUS+PFT,NT/CT
                  E AIDS/CT
                  E E4+ALL
L26        25011 SEA SPE=ON  ABB=ON  "AIDS (DISEASE)"+PFT/CT
                  E ANTI-AIDS AGENTS+ALL/CT
L27        24255 SEA SPE=ON  ABB=ON  ANTI-AIDS AGENTS/CT
L28           37 SEA SPE=ON  ABB=ON  (L19 OR L20 OR L21 OR L22 OR L23) AND L24
L29            3 SEA SPE=ON  ABB=ON  (L19 OR L20 OR L21 OR L22 OR L23) AND L24
                  AND (L25 OR L26 OR L27)
L30           13 SEA SPE=ON  ABB=ON  L24 AND (L25 OR L26 OR L27)
```

```
     FILE 'USPATFULL' ENTERED AT 09:42:53 ON 07 APR 2009
L31          63 SEA SPE=ON  ABB=ON  L12
L32          66 SEA SPE=ON  ABB=ON  TRACEY K?/AU
L33         147 SEA SPE=ON  ABB=ON  COHEN P?/AU
L34          17 SEA SPE=ON  ABB=ON  BUKRINSKY M?/AU
L35           3 SEA SPE=ON  ABB=ON  SCHMIDTMAYEROVA H?/AU
L36          18 SEA SPE=ON  ABB=ON  L31 AND (L32 OR L33 OR L34 OR L35)
L37       63858 SEA SPE=ON  ABB=ON  HIV# OR HUMAN(W)(IMMUN? DEFICIEN? OR
                IMMUNODEFIC?)
L38      219327 SEA SPE=ON  ABB=ON  AIDS OR ACQUIRED(W)(IMMUN? DEFICIEN? OR
                IMMUNODEFIC?)
L39       56681 SEA SPE=ON  ABB=ON  RETROVIR? OR ANTIRETROVIR?
L40           4 SEA SPE=ON  ABB=ON  L31 AND (L32 OR L33 OR L34 OR L35) AND
                (L37 OR L38 OR L39)
L41          25 SEA SPE=ON  ABB=ON  L31 AND (L37 OR L38 OR L39)
L42           0 SEA SPE=ON  ABB=ON  L41 AND (PD<19961114 OR AD<19961114 OR
                PRD<19961114)

     FILE 'HCAPLUS' ENTERED AT 09:46:27 ON 07 APR 2009
L43          10 SEA SPE=ON  ABB=ON  L30 AND PATENT/DT
L44           0 SEA SPE=ON  ABB=ON  L30 AND REVIEW/DT
L45           3 SEA SPE=ON  ABB=ON  L30 NOT L43
L46           0 SEA SPE=ON  ABB=ON  L45 AND PY<1997
L47           0 SEA SPE=ON  ABB=ON  L43 AND (PD<19961114 OR AD<19961114 OR
                PRD<19961114)
L48           0 SEA SPE=ON  ABB=ON  (L46 OR L47)
L49       24429 SEA SPE=ON  ABB=ON  RETROVIR?/OBI OR ANTIRETROVIR?/OBI
L50           3 SEA SPE=ON  ABB=ON  L24 AND L49
L51          14 SEA SPE=ON  ABB=ON  (L50 OR L30)
L52          11 SEA SPE=ON  ABB=ON  L51 AND PATENT/DT
L53           3 SEA SPE=ON  ABB=ON  L51 NOT L52
L54           0 SEA SPE=ON  ABB=ON  L53 AND PY<1997
L55           0 SEA SPE=ON  ABB=ON  L51 AND (PD<19961114 OR AD<19961114 OR
                PRD<19961114)
L56           0 SEA SPE=ON  ABB=ON  (L54 OR L55)

     FILE 'STNGUIDE' ENTERED AT 09:48:48 ON 07 APR 2009

     FILE 'HCAPLUS' ENTERED AT 09:49:13 ON 07 APR 2009
                D QUE NOS L29

     FILE 'USPATFULL' ENTERED AT 09:49:14 ON 07 APR 2009
                D QUE NOS L40

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 09:49:18 ON 07 APR 2009
L57           7 DUP REM L29 L40 (0 DUPLICATES REMOVED)
                     ANSWERS '1-3' FROM FILE HCAPLUS
                     ANSWERS '4-7' FROM FILE USPATFULL
                D IBIB ABS HITIND HITSTR 1-7

     FILE 'REGISTRY' ENTERED AT 09:49:52 ON 07 APR 2009
                D STAT QUE L12

     FILE 'HCAPLUS' ENTERED AT 09:50:03 ON 07 APR 2009
                D QUE NOS L56
                D QUE NOS L51
L58          11 SEA SPE=ON  ABB=ON  L51 NOT L29

     FILE 'USPATFULL' ENTERED AT 09:50:30 ON 07 APR 2009
                D QUE NOS L42
```

```
                D QUE NOS L41
L59           21 SEA SPE=ON  ABB=ON  L41 NOT L40

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 09:50:36 ON 07 APR 2009
L60           29 DUP REM L58 L59 (3 DUPLICATES REMOVED)
                    ANSWERS '1-11' FROM FILE HCAPLUS
                    ANSWERS '12-29' FROM FILE USPATFULL
                D IBIB ABS HITIND HITSTR 1-29

     FILE 'HOME' ENTERED AT 09:51:01 ON 07 APR 2009
                D STAT QUE L12
```